ESMO news item · 2026-09-17

On 2026-09-17 ESMO (European Society for Medical Oncology) published on its official news channel an item concerning non-small cell lung cancer (NSCLC).

Original title of the item, according to ESMO: «Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC».

This page does not reproduce the text of the ESMO item: it only reports the identifying details and refers to the official source for the full content.

Note: press release, not peer-reviewed.

Source: ESMO — https://www.esmo.org/oncology-news/perioperative-durvalumab-continues-to-show-clinical-benefit-in-patients-with-resectable-stage-iia-to-iiib-nsclc